Table 3. Primary and secondary endpoint of patients with AMI.
| Characteristic | Total (n=1,309), n (%) | β-blockers (n=1,074), n (%) | Non β-blockers (n=235), n (%) | P value |
|---|---|---|---|---|
| CIN 0.5 | 76 (5.8) | 42 (3.9) | 34 (14.5) | <0.001 |
| Post-dialysis | 28 (2.1) | 17 (1.6) | 11 (4.7) | 0.003 |
| In-hospital death | 53 (4.0) | 29 (2.7) | 24 (10.2) | <0.001 |
| Follow-up death | 77 (5.9) | 43 (4.0) | 34 (14.5) | <0.001 |
| In-hospital MACE | 115 (8.8) | 74 (6.9) | 41 (17.4) | <0.001 |
| Follow-up MACE | 96 (7.3) | 59 (5.5) | 37 (15.7) | <0.001 |
CI-AKI, contrast-induced acute kidney injury; MACE, major adverse cardiovascular events.